Safety and Tolerability of Preservative-free Polyhexamethylene Biguanide (PHMB) Ophthalmic Soluti… (NCT02506257) | Clinical Trial Compass
CompletedPhase 1
Safety and Tolerability of Preservative-free Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Healthy Subjects
90 participantsStarted 2015-11
Plain-language summary
Randomized, double-masked, placebo-controlled, multiple center, parallel-group Phase 1 study to evaluate the safety and tolerability of 3 doses of preservative-free PHMB ophthalmic solution compared to placebo in healthy subjects
Who can participate
Age range
18 Years – 55 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* able and willing to give informed consent.
* man or woman of any race and 18 to 55 years of age, inclusive.
* Body Mass Index of 20-30 kg/m2
* willing and able to attend required study visits.
* bilateral visual acuity \>6/10.
* intraocular pressure (IOP) of 14-21 mmHg.
* ophthalmologic examination without abnormalities.
* medical history without major pathology.
* laboratory test results without deviations from the normal range.
* female subjects of childbearing potential with negative urine pregnancy test and using effective contraception during the study.
Exclusion Criteria:
* presence of bacterial ocular infections.
* presence of any concomitant ocular pathology.
* performing activities likely to result in an irritated conjunctiva during the study (including heavy alcohol intake, swimming in chlorinated water and heavy smoking).
* contact lenses wearing .
* ocular surface fluorescein staining score \>3.
* use of topical or systemic antibiotics, antihistamines, decongestants and non-steroidal anti-inflammatory agents as well as steroids within 7 days before screening.
* known or suspected allergy to biguanides or intolerance to any other ingredient of the test treatments.
* ocular surgery performed within 12 months before screening.
* participation in another clinical study in the preceding 30 days.
* one functional eye.
* pregnancy or breastfeeding.
* use of recreational drugs.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Number of Subjects With Dose-limiting Adverse Events
Timeframe: up to 21 days from date of randomization